Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Apple

Alibaba

CVS Health

Farfetch

Morgan Stanley

Pfizer

Everyone is on the hunt for undervalued stocks. Keep in mind, even more highly valued stocks can be undervalued.

7 Undervalued Stocks to Buy Now

Checkmate Pharmaceuticals (CMPI) inks deal with Bristol Myers to evaluate the combination of its CMP-001 and the latter's Opdivo.

Checkmate (CMPI), Bristol Myers Ink Deal for Cancer Combo

Bristol Myers stock has slipped this year. But acquiring Celgene has bolstered the pharmaceutical company's sales, and the pending acquisition of MyoKardia might also.

Bristol Myers Announced Another Major Acquisition — But Is BMY Stock A Buy?

NAPLES, Fla.--(BUSINESS WIRE)--Pentwater Capital Management LP ("Pentwater"), one of the largest holders of the Contingent Value Rights (“CVR”) (NYSE: BMY-R) distributed as part of the merger of Bristol-Myers Squibb Company (“BMS”) (NYSE:BMY) and Celgene Corporation, wishes to notify all holders of the CVR of the opportunity to replace the current trustee in order to protect their current and future rights. Each CVR entitles its holder to receive $9.00 in cash if the FDA approves three BMS drug

Pentwater Solicits Holders of Bristol-Myers Squibb Contingent Value Rights to Provide Consent to Replace Trustee

Intel

Kinder Morgan

Cheap dividend stocks can generate a double dose of returns, with dividends as well as capital appreciation through a rising share price. The post 3 Cheap Dividend Stocks For High Total Returns appeared first on InvestorPlace.

3 Cheap Dividend Stocks For High Total Returns

PRINCETON, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)---- $BMY #BMS--Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry

Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH20--BMS Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® in Adults with Acute Myeloid Leukemia in First Remission

Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission

The contingent value right issued to Celgene shareholders after the Bristol-Myers acquisitions are dependent on approval of Liso-cell and Ide-cell. For Liso-cell to be approved the FDA seems insistent on inspection of a Texas-based Lonza facility.

Bristol-Myers Squibb Contingent Value Rights: Final Inspection Is Happening

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH2020--Bristol Myers Squibb Presents Data Evaluating Potential of Liso-cel Across Leukemia and Lymphomas at ASH 2020

Bristol Myers Squibb Presents Data Evaluating Potential of Liso-cel Across Leukemia and Lymphomas at ASH 2020

Aflac

Bayer AG

Bank of Nova Scotia

Cisco Systems

Federal Realty Investment Trust

General Dynamics

Merck

Prudential Financial

Simon Property Group

Unum

The time has come once again to look at what sort of companies you'll want to be buying, this time as we move into December 2020. Rather than offering some sort of collective "list" that could potentially be hard to offer a clear overview, I go sector by sector and present 1-2 alternatives.

December 2020 Stocks: Financials, Real Estate, Industrials, IT, And Pharma

AbbVie

The Oracle of Omaha knows a good bargain when he sees one.

3 Value Stocks Warren Buffett Owns That You Should Consider Buying Too

Bristol Myers (BMY) reported earnings 30 days ago. What's next for the stock?

Bristol Myers (BMY) Down 2.3% Since Last Earnings Report: Can It Rebound?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AML--BMS Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic & Cell Therapies at ASH

Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020

In August, analysts and investors were wondering what Bristol-Myers Squibb Co. (NYSE:BMY) could do to reverse the sales decline for one of its blockbuster drugs. This is certainly a legitimate concern considering revenue from the company's cancer treatment, Optivo, declined 9% year over year in the second quarter and another 2% in the three months ending Sept.

New Uses Could Boost Sales of Bristol-Myers and Merck Drugs

NextEra Energy

It's time for opportunistic investors to put their money to work.

Got $300? 3 Surefire Stocks to Buy for a Young Bull Market

Home Depot

MetLife

Microsoft

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walmart

The stress of the election is finally over, and investors are euphoric about the vaccine. However, not all is well.

Top Dividend Stocks For December

Berkshire's latest filing revealed the Oracle of Omaha and his team opening new positions in four pharma giants as of late. From a quality standpoint, all companies seem like a natural fit considering Buffett's reported preference for wide-moat businesses.

Buffett Buys Pharma: Two Out Of Four Seem Compelling

Allogene Therapeutics Inc

Atara Biotherapeutics

Cellectis SA

CRISPR Therapeutics

Gilead Sciences

Novartis

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy.

Regenerative Medicines: Universal Cell Therapy Gaining Momentum

Despite solid gains in pharma sales and profits, Big Pharma's overall share value has pretty much stagnated over the past five years—but better days appear to be ahead, in my opinion.

Berkshire Hathaway Makes Big Bet on Pharma

Bank of America

General Motors

Kroger

Liberty Latin America

Snowflake

T-Mobile US

In this article we'll run through the Top 10 Stocks Warren Buffett Just Bought. If you're in a hurry to see the hedge fund legend's highest conviction new stock purchases, you can jump straight to the Top 5 Stocks Warren Buffett Just Bought .

Top 10 Stocks Warren Buffett Just Bought

Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn't mean that they don't have occasional colossal losses; they do (like Peltz's recent General Electric losses). However, it is still a good idea to keep an eye on hedge fund activity. With this in mind, as the current round of 13F filings has just ended, let's examine the smart money sentiment towards Bristol Myers Squibb Company (NYSE:BMY).

Do Hedge Funds Love Bristol Myers Squibb Company (BMY) As Much As Buffett Does?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal....

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Generation PMCA recently released its Q3 2020 Investor Letter. The fund is managed by co-founders Randall Abramson and Herb Abramson. The investment firm serves its clients through two distinct areas: Portfolio Management and Capital Advisory services. You should check out Generation PMCA's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Is Bristol-Myers Squibb (BMY) a Smart Long-term Buy?

Schrodinger 

Schrödinger Inc. shares jumped about 8% in premarket trade Monday, after the company announced a drug discovery agreement with Bristol Myers Squibb Co. that could net it up to $2.7 billion in milestone payments and royalties. Schrödinger, which offers a physics-based software platform that can speed up drug development and lower costs, will receive $55 million upfront.

News for Bristol-Myers Stock (BMY)